MedTrace Logo

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

NCT00717262 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2009-01-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, activity and pharmacokinetics of a new investigational drug (HQK-1001) in healthy human volunteers. This study will also evaluate if there are differences in these parameters when HQK-1001 is administered in a fed versus a fasted state.

Conditions

  • Healthy

Interventions

DRUG

HQK-1001

HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.

DRUG

placebo

Matching placebo capsules administered once a day, orally, for 14 days.

Sponsors & Collaborators

  • HemaQuest Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Robin Downey, MD · Charles River Clinical Services Northwest

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-08-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00717262 on ClinicalTrials.gov